Early outcomes of breast cancer patients treated with post-mastectomy uniform scanning proton therapy.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
03 2019
Historique:
received: 17 04 2018
revised: 28 09 2018
accepted: 01 10 2018
pubmed: 12 11 2018
medline: 4 3 2020
entrez: 12 11 2018
Statut: ppublish

Résumé

Postmastectomy proton radiotherapy improves normal tissue sparing in comparison to photon-based approaches. Several studies have reported dosimetry comparison and tolerable acute toxicity profile with limited follow-up. We report our institutional experience of postmastectomy proton radiation including clinical efficacy and toxicities. From December 2013 to February 2015, 42 consecutive patients who received mastectomy for non-metastatic breast cancer were treated with adjuvant chest wall and regional nodal proton therapy at a single proton center. 3D conformal uniform scanning with en face matching fields was used. The median follow-up among patients was 35 months (range 1-55 months). There was one local failure, zero regional nodal failure, and six distant failures. The 3-year rate of locoregional disease-free survival was 96.3%, metastasis-free survival was 84.1%, and overall survival was 97.2%. The only local failure event occurred on the chest wall within the radiation field, approximately 2.5 years after the completion of radiation. Skin dermatitis, fatigue, and esophagitis were the most common acute toxicity. All patients developed grade 1 or 2 acute skin toxicity and there was no grade 3 or 4 acute skin toxicity. Proton radiation is able to achieve excellent target coverage with median PTV V95 over 95% and heart sparing with median mean heart dose less than 1 Gy (RBE). With close to three years of median follow-up, post-mastectomy proton radiation has shown excellent locoregional control rates and favorable toxicity profile. Long-term adverse effect of heart-sparing radiation will require longer follow-up time and randomized clinical trials.

Sections du résumé

BACKGROUND
Postmastectomy proton radiotherapy improves normal tissue sparing in comparison to photon-based approaches. Several studies have reported dosimetry comparison and tolerable acute toxicity profile with limited follow-up. We report our institutional experience of postmastectomy proton radiation including clinical efficacy and toxicities.
METHODS
From December 2013 to February 2015, 42 consecutive patients who received mastectomy for non-metastatic breast cancer were treated with adjuvant chest wall and regional nodal proton therapy at a single proton center. 3D conformal uniform scanning with en face matching fields was used.
RESULTS
The median follow-up among patients was 35 months (range 1-55 months). There was one local failure, zero regional nodal failure, and six distant failures. The 3-year rate of locoregional disease-free survival was 96.3%, metastasis-free survival was 84.1%, and overall survival was 97.2%. The only local failure event occurred on the chest wall within the radiation field, approximately 2.5 years after the completion of radiation. Skin dermatitis, fatigue, and esophagitis were the most common acute toxicity. All patients developed grade 1 or 2 acute skin toxicity and there was no grade 3 or 4 acute skin toxicity. Proton radiation is able to achieve excellent target coverage with median PTV V95 over 95% and heart sparing with median mean heart dose less than 1 Gy (RBE).
CONCLUSION
With close to three years of median follow-up, post-mastectomy proton radiation has shown excellent locoregional control rates and favorable toxicity profile. Long-term adverse effect of heart-sparing radiation will require longer follow-up time and randomized clinical trials.

Identifiants

pubmed: 30414757
pii: S0167-8140(18)33507-2
doi: 10.1016/j.radonc.2018.10.002
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

250-256

Informations de copyright

Copyright © 2018 Elsevier B.V. All rights reserved.

Auteurs

Leo Luo (L)

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States. Electronic address: luol1@mskcc.org.

John Cuaron (J)

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.

Lior Braunstein (L)

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.

Erin Gillespie (E)

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.

Atif Kahn (A)

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.

Beryl McCormick (B)

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.

Dennis Mah (D)

Procure Proton Therapy Center, Somerset, New Jersey 08873, United States.

Brian Chon (B)

Procure Proton Therapy Center, Somerset, New Jersey 08873, United States.

Henry Tsai (H)

Procure Proton Therapy Center, Somerset, New Jersey 08873, United States.

Simon Powell (S)

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.

Oren Cahlon (O)

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States. Electronic address: cahlono@mskcc.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH